Effect of Cholecalciferol Therapy on Serum FGF in Vitamin D Deficient Patients: a Randomized Clinical Trial

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2017 Aug 11

PMID 28795342

Citations 11

Authors

T Kamelian

F Saki

M Jeddi

M H Dabbaghmanesh

G H R Omrani

Affiliations

Soon will be listed here.

Abstract

Introduction: Fibroblast growth factor-23 plays an important role in regulating systemic phosphate homeostasis, and vitamin D metabolism. However, the effect of Cholecalciferol therapy on FGF serum level in patients with vitamin D deficiency has not been studied, yet.

Materials And Methods: This is a double-blind, randomized clinical trial on 119 vitamin D deficient patients in 2016. Biochemical variables of treatment and placebo groups were analyzed after 12 weeks of 50,000 IU of Cholecalciferol vs. placebo therapy once a week, by SPSS18.

Results: After Cholecalciferol therapy, delta of serum PTH in treatment group was less than the controls (P < 0.001). However, delta values of serum 25(OH)D, 1,25(OH)D and FGF in vitamin D treated group were more than the placebo-treated ones (P < 0.001, P = 0.002, and P = 0.04, respectively). Moreover, FGF serum level in treatment group was associated with serum calcium (P = 0.005, r = -0.256), and serum 1,25(OH)D (P < 0.001, r = 0.529).

Conclusions: We propose that in these patients 1,25(OH)D has a positive association with serum FGF, and hypostasized that serum calcium might be a down regulator of serum FGF.

Citing Articles

Vitamin D supplementation in primary hyperparathyroidism: effects on 1,25(OH) vitamin D and FGF23 levels.

Pallone S, Ohe M, Dos Santos L, Nacaguma I, Kunii I, da Silva R J Endocrinol Invest. 2024; 48(1):91-98.

PMID: 38922369 DOI: 10.1007/s40618-024-02422-2.

Non-Classical Effects of FGF23: Molecular and Clinical Features.

Martinez-Heredia L, Canelo-Moreno J, Garcia-Fontana B, Munoz-Torres M Int J Mol Sci. 2024; 25(9).

PMID: 38732094 PMC: 11084844. DOI: 10.3390/ijms25094875.

Mineral Metabolism in Children: Interrelation between Vitamin D and FGF23.

Pons-Belda O, Alonso-Alvarez M, Gonzalez-Rodriguez J, Mantecon-Fernandez L, Santos-Rodriguez F Int J Mol Sci. 2023; 24(7).

PMID: 37047636 PMC: 10094813. DOI: 10.3390/ijms24076661.

Effect of vitamin D supplementation on circulating fibroblast growth factor-23 concentration in adults with prediabetes.

Ceglia L, Pittas A, Dawson-Hughes B Aging Clin Exp Res. 2023; 35(3):525-530.

PMID: 36631721 DOI: 10.1007/s40520-022-02338-y.

New concepts in regulation and function of the FGF23.

Dastghaib S, Koohpeyma F, Shams M, Saki F, Alizadeh A Clin Exp Med. 2022; 23(4):1055-1066.

PMID: 35708778 DOI: 10.1007/s10238-022-00844-x.

References

Ashouri E, Meimandi E, Saki F, Dabbaghmanesh M, Ranjbar Omrani G, Bakhshayeshkaram M . The impact of LRP5 polymorphism (rs556442) on calcium homeostasis, bone mineral density, and body composition in Iranian children. J Bone Miner Metab. 2014; 33(6):651-7. DOI: 10.1007/s00774-014-0624-4. View

Hsu H, Wu M . Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337(2):116-22. DOI: 10.1097/MAJ.0b013e3181815498. View

Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S . Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2004; 280(4):2543-9. DOI: 10.1074/jbc.M408903200. View

Wetmore J, Liu S, Krebill R, Menard R, Quarles L . Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol. 2009; 5(1):110-6. PMC: 2801647. DOI: 10.2215/CJN.03630509. View

Havens P, Hazra R, Stephensen C, Kiser J, Flynn P, Wilson C . Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate. Antivir Ther. 2014; 19(6):613-8. PMC: 4135028. DOI: 10.3851/IMP2755. View

Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T . Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005; 289(5):F1088-95. DOI: 10.1152/ajprenal.00474.2004. View

Saki F, Dabbaghmanesh M, Ranjbar Omrani G, Bakhshayeshkaram M . Vitamin D deficiency and its associated risk factors in children and adolescents in southern Iran. Public Health Nutr. 2015; 20(10):1851-1856. PMC: 10261289. DOI: 10.1017/S1368980015001925. View

Liu S, Tang W, Zhou J, Stubbs J, Luo Q, Pi M . Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006; 17(5):1305-15. DOI: 10.1681/ASN.2005111185. View

Hruska K, Rifas L, Cheng S, Gupta A, Halstead L, Avioli L . X-linked hypophosphatemic rickets and the murine Hyp homologue. Am J Physiol. 1995; 268(3 Pt 2):F357-62. DOI: 10.1152/ajprenal.1995.268.3.F357. View

10.

Clinkenbeard E, White K . Systemic Control of Bone Homeostasis by FGF23 Signaling. Curr Mol Biol Rep. 2016; 2(1):62-71. PMC: 4847743. DOI: 10.1007/s40610-016-0035-5. View

11.

Fliser D, Kollerits B, Neyer U, Ankerst D, Lhotta K, Lingenhel A . Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18(9):2600-8. DOI: 10.1681/ASN.2006080936. View

12.

Kolek O, Hines E, Jones M, LeSueur L, Lipko M, Kiela P . 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005; 289(6):G1036-42. DOI: 10.1152/ajpgi.00243.2005. View

13.

Kazama J, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H . Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int. 2005; 67(3):1120-5. DOI: 10.1111/j.1523-1755.2005.00178.x. View

14.

Haussler M, Whitfield G, Haussler C, Hsieh J, Thompson P, Selznick S . The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998; 13(3):325-49. DOI: 10.1359/jbmr.1998.13.3.325. View

15.

Prie D, Friedlander G . Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol. 2010; 5(9):1717-22. DOI: 10.2215/CJN.02680310. View

16.

Burnett-Bowie S, Leder B, Henao M, Baldwin C, Hayden D, Finkelstein J . Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol. 2012; 7(4):624-31. PMC: 3315336. DOI: 10.2215/CJN.10030911. View

17.

Soliman A, De Sanctis V, Elalaily R, Bedair S, Kassem I . Vitamin D deficiency in adolescents. Indian J Endocrinol Metab. 2014; 18(Suppl 1):S9-S16. PMC: 4266875. DOI: 10.4103/2230-8210.145043. View

18.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y . FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3):429-35. DOI: 10.1359/JBMR.0301264. View

19.

Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S . Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab. 2005; 288(6):E1101-9. DOI: 10.1152/ajpendo.00502.2004. View

20.

Haussler M, Whitfield G, Kaneko I, Forster R, Saini R, Hsieh J . The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord. 2011; 13(1):57-69. PMC: 3288475. DOI: 10.1007/s11154-011-9199-8. View